İleri Evre Akciğer Kanserinde; Yaygın Kanser İnflamasyon İndeksi (ALI), Serum Nötrofil/Lenfosit Oranı (NLR), Trombosit/Lenfosit Oranının (PLR) Prognostik Değeri

Amaç: Akciğer kanseri tüm dünyada en sık görülen ve ölüme neden olan kanser türüdür. Sistemik inflamasyon hem kanser etiyopatogenezinde rol oynadığı hem de kanser hücrelerinde onkojenik değişikliklerden aktiflenebildiği gösterilmiştir. Akciğer kanserinde, prognozunu ve riskli olguları belirlemede sistemik inflamatuar parametrelerin yeri olabileceğini gösteren çalışmalar olmakla beraber sonuçlar halen tartışmalıdır. Çalışmamızda serumdan hesaplanan inflamatuar parametrelerin, akciğer kanserinde prognostik etkisi araştırıldı. Yöntem: Göğüs hastalıkları kliniğimizde 2013-2015 tarihleri arasında tanı alan lokal ileri ve ileri evre akciğer kanserli 115 olgu retrospektif olarak incelendi. Tüm hastaların tanı aşamasında serum örneklerinden hesaplanan; ileri akciğer kanseri inflamasyon indexi (ALI indeksi), serum nötrofil/lenfosit oranı (NLR), trombosit/lenfosit oranı (PLR) düzeyleri ile genel sağkalım (OS), hastalıksız sağkalım (PFS) ve tedaviye yanıt değerlendirmeleri arasındaki ilişki ve prognozu öngörmede ki etkisi araştırıldı. Bulgular: Çalışmamızda ileri evre akciğer kanserli olgular da OS için incelendiğinde; ALI ve NLR de istatistiksel olarak anlamlı (p

Prognostic Value of Diffuse Cancer Inflammation Index (ALI), Serum Neutrophil/Lymphocyte Ratio (NLR) and Platelet/lymphocyte Ratio (PLR) in Advanced Stage Lung Cancer

Objective: Lung cancer (Ca) is the most common type of cancer that causes death worldwide. Systemic inflammation has been shown to play a role in cancer etiopathogenesis and can be activated from oncogenic changes in cancer cells. In lung cancer, although there are studies showing that systemic inflammatory parameters may have a role in determining prognosis and risky cases, the results are still controversial. In our study, the prognostic effects of inflammatory parameters calculated from serum were investigated in lung Ca. Method: One hundred fifteen patients with locally advanced and advanced lung cancer who were diagnosed in our chest diseases clinic between 2013 and 2015 were retrospectively analyzed. The relationship between advanced lung cancer inflammation index (ALI index), serum neutrophil/ lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR) levels at the time of diagnosis were calculated, and their relationship with overall survival (OS), disease-free survival (PFS) and the treatment response and their effect on predicting prognosis were investigated. Results: In our study, when advanced lung cancer cases were examined regarding OS; ALI, and NLR were statistically significant (p

___

  • 1. Bunn A. Paul. Worldwide Overview of the Current Status of Lung Cancer Diagnosis and Treatment. Arch. Pathol. Lab. Med. 2012;136:1478-81. https://doi.org/10.5858/arpa.2012-0295-SA
  • 2. Hussain S P, Harris C C. Inflammation and cancer: an ancient link with novel potentials. Int J Cancer. 2007; 121:2373-80. https://doi.org/10.1002/ijc.23173
  • 3. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer - related inflammation. Nature. 2008;454(7203):436-44. https://doi.org/10.1038/nature07205
  • 4. Coussens L M, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860-7. https://doi.org/10.1038/nature01322
  • 5. Cedres S, Torrejon D, Martinez A, Martinez P, Navarro A, Zamora E, et al. Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer. Clin Transl Oncol. 2012;14(11):864-9. https://doi.org/10.1007/s12094-012-0872-5
  • 6. Yao Y, Yuan D, Liu H, Gu X, Song Y. Pretreatment neutrophil to lymphocyte ratio is associated with response to therapy and prognosis of advanced nonsmall cell lung cancer patients treated with first-line platinum-based chemotherapy. Cancer Immunol Immunother. 2013;62(3):471-9. https://doi.org/10.1007/s00262-012-1347-9
  • 7. Hong X, Cui B, Wang M, Yang Z, Wang L, Xu Q. Systemic immune - inflammation index, based on platelet counts and neutrophil - lymphocyte ratio, is useful for predicting prognosis in small cell lung cancer. Tohoku J Exp Med. 2015;236(4):297-304. https://doi.org/10.1620/tjem.236.297
  • 8. Unal D, Eroglu C, Kurtul N, Oguz A, Tasdemir A. Are neutrophil/lymphocyte and platelet/lymphocyte rates in patients with non - small cell lung cancer associated with treatment response and prognosis?. Asian Pacific Journal of Cancer Prevention. 2013;14(9):5237-42. https://doi.org/10.7314/APJCP.2013.14.9.5237
  • 9. Wu G, Yao Y, Bai C, Zeng J, Shi D, Gu X, et al. A combination of platelet to lymphocyte ratio and neutrophil to lymphocyte ratio is a useful prognostic factor in advanced non-small cell lung cancer patients. Thoracic Cancer. 2015;6(3):275-87. https://doi.org/10.1111/1759-7714.12178
  • 10. McMillan D C, Watson W S, O’Gorman P, Preston T, Scott H R, McArdle C S. Albumin concentrations are primarily determined by the body cell mass and the systemic inflammatory response in cancer patients with weight loss. Nutr Cancer. 2001;39(2):210-3. https://doi.org/10.1207/S15327914nc392_8
  • 11. Jafri S H, Shi R, Mills, G. Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review. BMC Cancer. 2013;13(1):158. https://doi.org/10.1186/1471-2407-13-158
  • 12. He X, Zhou T, Yang Y, Hong S, Zhan J, Hu Z, et al. Advanced lung cancer inflammation index, a new prognostic score, predicts outcome in patients with small-cell lung cancer. Clinical lung cancer. 2015;16(6): e165-e171. https://doi.org/10.1016/j.cllc.2015.03.005
  • 13. Hua X, Chen J, Wu Y, Sha J, Han S, Zhu, X. Prognostic role of the advanced lung cancer inflammation index in cancer patients: a meta-analysis. World journal of surgical oncology. 2019;17(1):177. https://doi.org/10.1186/s12957-019-1725-2
  • 14. Zhang Y, Chen B. Prognostic Value of the Advanced Lung Cancer Inflammation Index in Patients with Lung Cancer: A Meta-Analysis. Disease markers. 2019. https://doi.org/10.1155/2019/2513026